From January to September 2019, the ex factory price of pharmaceutical manufacturing industry increased by 2% year on year

[industry trends of pharmaceutical network] according to the website of the National Bureau of statistics, in September 2019, the factory price of national industrial producers dropped 1.2% year on year and rose 0.1% month on month; the purchase price of industrial producers fell 1.7% year on year and rose 0.2% month on month From January to September, on average, the ex factory price of industrial producers was the same as that of the same period last year, and the purchase price of industrial producers fell by 0.3% According to the main data of industrial producer prices in September 2019, in terms of the ex factory prices of pharmaceutical manufacturing industry, the month on month drop was 0%, up 1.1% year on year, and the year-on-year increase from January to September was 2% From January to September 2019, with the promotion of China's policies of generic drug consistency evaluation, volume purchase, etc., and the deepening of transformation and upgrading of the pharmaceutical industry, some pharmaceutical enterprises increased their investment layout in emerging pharmaceutical fields, and under the background of people's growing demand for related pharmaceutical products, the pharmaceutical manufacturing industry has been growing rapidly According to the data of the National Bureau of statistics, in the first half of 2019 alone, the operating revenue of Enterprises above the designated size in China's pharmaceutical manufacturing industry reached 1222.75 billion yuan, an increase of 8.5% year on year, and the total profit was about 160.82 billion yuan, an increase of 9.4% year on year In terms of pharmaceutical manufacturing industry, it can be divided into Chinese patent medicine, chemical medicine preparation and other parts Among them, in the Chinese patent medicine industry, according to the statistics of the National Bureau of statistics, the output of Chinese patent medicine in the whole country increased gradually in the first two quarters of 2019 As of July 2019, the output of Chinese patent medicine in the whole country was 205000 tons, down 10.5% year on year In cumulative terms, from January to July 2019, the output of Chinese patent medicine reached 1.494 million tons, down 7% year on year Chemical pharmaceutical manufacturing is a major sub industry of pharmaceutical manufacturing, and the growth rate of business income in recent years is basically the same as the average level of pharmaceutical manufacturing In 2019, under the general tone of medical insurance and fee control, the overall profit growth of China's chemical pharmaceutical industry slowed down However, under the background of aging population and increasing residents' income, the chemical pharmaceutical industry still maintained a rapid growth Under the influence of the policy of limited antibiotics and injection, the performance differentiation of chemical pharmaceutical industry has increased At the same time, under the pressure of environmental protection, safety and other regulatory measures, the pharmaceutical industry has entered a critical period of survival of the fittest, and the differentiation of pharmaceutical enterprises will be further intensified The chemical preparation enterprises with strong R & D strength, high product quality and clear curative effect have strong competitive advantages, and pharmaceutical manufacturers such as auxiliary drugs and nutritional drugs will face greater business pressure In this context, some pharmaceutical enterprises have taken positive measures For example, some pharmaceutical enterprises adopt a variety of sales modes in pharmaceutical industrial products, while pharmaceutical business includes pharmaceutical wholesale business and retail business Through continuous improvement of the company's quality management system, strengthening the control of production and operation process, improving the level of quality awareness of all employees, providing fundamental guarantee for the safety and effectiveness of product quality, and providing solid quality assurance for the development of enterprises In general, because the chemical pharmaceutical market in our country is basically dominated by generic drugs, in 2019, driven by the consistency evaluation of generic drugs and volume purchase, the industry reshuffle will be further intensified, the market competition pattern will change, and the survival competition of enterprises will be more obvious Especially with the nationwide expansion of volume procurement, the industry generally believes that the next step is to expand varieties after 25 varieties expansion regions Those varieties with large market scale and more enterprises passing the consistency evaluation have a higher probability of being selected.